Green S M, Rothrock S G, Ho J D, Gallant R D, Borger R, Thomas T L, Zimmerman G J
Department of Emergency Medicine, Loma Linda University School of Medicine, CA, USA.
Ann Emerg Med. 1998 Jan;31(1):41-8. doi: 10.1016/s0196-0644(98)70279-3.
Although adjunctive intravenous bicarbonate therapy is commonly recommended for children with severe diabetic ketoacidosis (DKA), no studies assessing clinical outcome with this therapy have ever been performed. Our objective was to determine whether bicarbonate therapy influenced outcome for pediatric DKA.
The study was a retrospective consecutive case series of 147 admissions for severe DKA (initial pH < or = 7.15 and glucose concentration > or = 300 mg/dL [16.7 mmol/L]) in 106 children during a 16-year period at a tertiary university medical center. Descriptive statistics were applied to the 147 admissions. The first patient admitted with DKA was then selected for each of the 106 children, and clinical and laboratory data were compared between subjects who did and did not receive bicarbonate. Multivariate and matched pair analyses were performed to control potentially confounding variables.
Fifty-seven of the 147 patients admitted with DKA (39%) were successfully treated without bicarbonate, including 9 with a pH of 7.00 or less and one with a pH of 6.73. The frequency of complications was comparable between bicarbonate and nonbicarbonate groups (4% versus 2%, P = 1.00). The mean duration of hospitalization for children receiving bicarbonate was 23% (16 hours) longer than children who did not receive bicarbonate in the multivariate analysis (P = .07) and 37% (22 hours) longer in the matched pair analysis (P = .01). The mean rate of metabolic recovery by three distinct measures was similar between groups, and the sample had 80% power to detect differences of 14% to 29% in these measures.
We found no evidence that adjunctive bicarbonate improved clinical outcome in children with severe DKA. The rate of metabolic recovery and complications were similar in patients treated with and without bicarbonate, and prolonged hospitalizations were noted in the bicarbonate group. We conclude that adjunctive bicarbonate is unnecessary and potentially disadvantageous in severe pediatric DKA.
尽管通常建议对患有严重糖尿病酮症酸中毒(DKA)的儿童进行静脉注射碳酸氢盐辅助治疗,但尚未有评估该疗法临床疗效的研究。我们的目的是确定碳酸氢盐治疗是否会影响小儿DKA的治疗结果。
该研究是一项回顾性连续病例系列研究,在一所三级大学医学中心对106名儿童在16年期间因严重DKA(初始pH≤7.15且血糖浓度≥300mg/dL[16.7mmol/L])而进行的147次入院治疗进行了研究。对这147次入院治疗应用了描述性统计。然后为这106名儿童中的每一位挑选出首位因DKA入院的患者,并比较接受和未接受碳酸氢盐治疗的患者的临床和实验室数据。进行了多变量和配对分析以控制潜在的混杂变量。
147例因DKA入院的患者中有57例(39%)未使用碳酸氢盐成功治疗,其中9例pH值为7.00或更低,1例pH值为6.73。碳酸氢盐组和非碳酸氢盐组的并发症发生率相当(4%对2%,P = 1.00)。在多变量分析中,接受碳酸氢盐治疗的儿童的平均住院时间比未接受碳酸氢盐治疗的儿童长23%(16小时)(P = 0.07),在配对分析中长37%(22小时)(P = 0.01)。通过三种不同测量方法得出的代谢恢复平均速率在两组之间相似,并且该样本有80%的把握检测出这些测量方法中14%至29%的差异。
我们没有发现证据表明辅助使用碳酸氢盐可改善严重小儿DKA的临床疗效。接受和未接受碳酸氢盐治疗的患者的代谢恢复速率和并发症相似,并且碳酸氢盐组的住院时间延长。我们得出结论,在严重小儿DKA中,辅助使用碳酸氢盐是不必要的,而且可能具有不利影响。